Published date: 21 June 2021
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Pharmaceutical products - 33600000
Location of contract
East Midlands, East of England, London, North East, North West, South East, South West, West Midlands, Yorkshire and the Humber, Channel Islands, Isle of Man
Value of contract
£710,767,138
Procurement reference
CF-0218500D0O000000rwimUAA1
Published date
21 June 2021
Closing date
26 July 2021
Closing time
1pm
Contract start date
1 February 2022
Contract end date
31 May 2024
Contract type
Supply contract
Procedure type
Open procedure (below threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements below the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Tender Close: 26th July 2021, 13:00.
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)
Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)
Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months)
More information
Links
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nN/HWcptyRHiN0iTH6pWdnphE4NqOoh5Ayz8ffWr4rJaTM
- Document No. 09 - Stability Data Requirements
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nB/5TJmbuA3I3YUJYJlacRkq5dFamWcJ9lSNdho75oaKMo
- Document No. 00 - Read Me First Document
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1mx/7DZLy_mc15TxGtW101ZtPRVmJIv8xrTL3vtL5etsdnk
- Document No. 02 - Terms of offer
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1na/_.Uxru4eGKJuv1q.SUDDI0GhbuE5Cc4vO5DEZk.GJYE
- Document No. 07a - Quality control technical sheet
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nV/V3nlLWBpSNYOswaF2NN_JWdVVPHe34cQ4vl5vbhKq8w
- Document No. 05a (v) Product Listing and Usage Hospital Only
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nC/U6RJLEyypAEMFSIUo87dVai1A6_Crs39D92f28lRo2s
- Document No. 01 - Invitation to offer covering letter
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nS/S0CGPE34WHhYrVS4xiipiYvh_6fWvjclZNBC1IyLU5I
- Document No. 06 - Form of offer
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nf/s13sx0g5pfeDFVDdiAIXwHCqpPb.4qCVkQtnqKQD50w
- Document No. 07b - Guidance for Performing a Pharmaceutical Quality Assessment of Licensed Medicines for the NHS
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nQ/dynJ8xFeJ6bxbAwpJmDMwmY3D4CAtxW1G3PVB92yMYE
- Document No. 03 - Framework Agreement and Terms and Conditions
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nL/YJ7dfbIDenE1yF8R9J7NiR2WUm9ZmhY.UTdJDlZDgBQ
- Document No. 04 - Contract technical specification
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nM/U9jGL1j68pbP8oC7siJoJw22SetQakPKEweKlJEmGbs
- Document No. 05a (i) Product Listing and Usage Everolimus
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nW/x8YQQEhycg2MboT3v4DuEe_IzvBmi4fBy1LADZ97mmg
- Document No. 05a (ii), 05a (iv), 05a (vi) CM_PHG_17_5532 SELECTT Application
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1ng/BZ78U7s18yIOPaUKgwiTzyiTTwUgpgzzxvsRsW2NPjk
- Document No. 05a (iii) Product Listing and Usage Orals
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nR/uH_rF2f7XLR7ytf1r8M0WRuiVrXozmEYyZ_uI.aoHUQ
- Document No. 05b - Selectt offer schedule instructions
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1nD/FFusdEVpdcavxHM9kxStiCHZlh.GQfBEhzFMd_lbCWI
- Document No. 08 - Confidential information schedule
-
- https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000Q1ox/oJRk9p3S5CCKVZwp1rUK5o9LPmU0XSaxcFPwKkjhUg4
- FTS Notice - NHS National Generic Pharmaceuticals Wave 13
About the buyer
Contact name
Gemma Tomlinson / Lynne Tierney
Address
2nd Floor Rutland House
Runcorn
WA7 2ES
UK
Share this notice
Closing: 26 July 2021, 1pm
All content is available under the
